BRILINTA

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Ecuador, Hong Kong SAR China, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, Turkey.

Active ingredients

The drug BRILINTA contains one active pharmaceutical ingredient (API):

1	Ticagrelor UNII GLH0314RVC - TICAGRELOR
	Ticagrelor is an oral, direct acting, selective and reversibly binding P2Y12 receptor antagonist that prevents ADP-mediated P2Y12 dependent platelet activation and aggregation. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function has been shown to reduce the risk of CV events such as death, MI or stroke.
	Read more about Ticagrelor

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRILINTA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AC24	Ticagrelor	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1418P
BR	Câmara de Regulação do Mercado de Medicamentos	502306401116211, 502306402112218, 502306403119216, 502320120034207, 502320120034307
CA	Health Products and Food Branch	02368544, 02455005
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	3200-MEE-0418, 363031112
HK	Department of Health Drug Office	61187, 64706
IL	מִשְׂרַד הַבְּרִיאוּת	6678, 7933
JP	医薬品医療機器総合機構	3399011F1027, 3399011F2023
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	216M2011
NZ	Medicines and Medical Devices Safety Authority	14940, 17895
SG	Health Sciences Authority	14120P, 15294P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699786090286, 8699786090293, 8699786092785
US	FDA, National Drug Code	0186-0776, 0186-0777, 55154-9618
ZA	Health Products Regulatory Authority	44/8.2/1041